Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement

Phase 2

• Conditions: Spinal Tumors, Trauma Patients, Minocycline.
• Interventions: Drug: Minocycline; Drug: placebo

• Registration Number: NCT01813240
• Lead Sponsor: Hadassah Medical Organization

Brief Summary

Spinal cord trauma and the consequent paraplegia are possibly among the most devastating injuries in soldiers and during spine surgery, and are significant in the medical, social and financial aspects. Limited mobility, the need for assistance in all human activities, shame, and many medical complications related directly to the neural deficits make paraplegia an important target for prevention. Our study will evaluate the efficacy of Minocycline in two different groups:

1. Minimizing the neurological damage among trauma patients.

2. Preventing neurological damage through operation in spinal tumors patients.

2.OBJECTIVES

The primary objectives of the trial are to determine:

1. Efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients?

2. Efficacy of administrating minocycline at changing the natural history and rehabilitation of spinal cord trauma patients.

3. Safety of applying minocycline in spinal cord injuries patients and spinal cord tumors?

Detailed Description

Not available

Study Timeline

• Status Verified: 2013-03
• Study First Submitted: 2013-03-11
• Study First Submitted QC: 2013-03-15
• Last Update Submitted: 2013-03-15
• Study First Posted: 2013-03-18
• Last Update Posted: 2013-03-18
• Study Start: 2013-05
• Primary Completion: 2015-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 444

Inclusion Criteria

Trauma patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome).

1. Inclusion Criteria:
2. Patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome).
3. Ages: 18 to 65
4. Males - including those involved in active military duty.
5. Females - of child-bearing potential who have a negative pregnancy test (hCG urine) within 72 hours of informed consent. Pregnant women will be excluded from the study.

Exclusion Criteria

1. Complete cord transection, severe head injury, coma, or other disease of the CNS, and spinal injury diagnosed later than 24 hours.
2. Pregnant women (minocycline can cause fetal harm) and children.
3. Lower extremity fractures, mildly reduced consciousness and frail cognitive status will not be considered for exclusion.
4. Patients who will not be enrolled will be listed and reason for non inclusion will be recorded.

Spinal tumors:

Inclusion Criteria:

1. Intrathecal extramedullary tumors, vertebral metastases or primary vertebral tumors causing cord compression with or without incomplete cord syndrome.

Exclusion criteria:

1.Intramedullary tumors or tumors causing complete cord syndrome

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Minocycline, Trauma patuents, quality of life	Minocycline	-
Placebo, Trauma patients, quality of life	placebo	-
Placebo, Spinal cord tumors, quality of life	placebo	-
Minocycline, Spinal Tumor patients, quality of life	Minocycline	-

Primary Outcome Measures

Name	Time	Method
Efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients	six months	The Efficacy will be evaluated using the following measures: 1. ASIA SCORE - We will compare the results before administrating the study medication and after six months of follow up. The ASIA score will be the Primary Efficacy Endpoint.; 2. The Spinal Cord Independence Measure and Functional Independence Measure outcome scales.; 3. Objective reduction in lesion size by imaging modalities

Secondary Outcome Measures

Name	Time	Method
Efficacy of administrating minocycline at changing the natural history and rehabilitation of spinal cord trauma patients.	six months	The Efficacy will be evaluated using the following measures: 1. ASIA SCORE - We will compare the results before administrating the study medication and after six months of follow up. The ASIA score will be the Primary Efficacy Endpoint.; 2. The Spinal Cord Independence Measure and Functional Independence Measure outcome scales.; 3. Objective reduction in lesion size by imaging modalities
Safety of applying minocycline in spinal cord injuries patients and spinal cord tumors?	six months	Safety will be evaluated in a descriptive manner by recording all adverse events in the patient population by number and severity.; The study will evaluate safety by assessing: * Procedure related adverse events: * General adverse events: Adverse events not only directly related to the procedure, such as: complications related to anesthesia, hospitalization, or other general adverse events of unknown cause.

Trial Locations

Locations (1)

Hadassah Medical Organization; 🇮🇱 Jerusalem, Israel